Stockreport

Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off [Seeking Alpha]

Lexeo Therapeutics, Inc.  (LXEO) 
PDF Results from all cohorts of phase 1/2 LEAD study, using LX-1001 for the treatment of patients with homozygous APOE4 AD, expected 2nd half of 2024. The global Alzheime [Read more]